Market closed
Celldex/$CLDX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
Ticker
$CLDX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
160
Website
Celldex Metrics
BasicAdvanced
$1.5B
-
-$2.53
1.59
-
Price and volume
Market cap
$1.5B
Beta
1.59
52-week high
$53.18
52-week low
$20.91
Average daily volume
1M
Financial strength
Current ratio
24.268
Quick ratio
23.583
Long term debt to equity
0.217
Total debt to equity
0.393
Management effectiveness
Return on assets (TTM)
-19.73%
Return on equity (TTM)
-29.84%
Valuation
Price to revenue (TTM)
138.393
Price to book
1.92
Price to tangible book (TTM)
1.98
Price to free cash flow (TTM)
-8.647
Growth
Revenue change (TTM)
128.55%
Earnings per share change (TTM)
-4.15%
3-year revenue growth (CAGR)
7.18%
3-year earnings per share growth (CAGR)
12.95%
What the Analysts think about Celldex
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Celldex stock.
Celldex Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Celldex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Celldex News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Celldex stock?
Celldex (CLDX) has a market cap of $1.5B as of February 18, 2025.
What is the P/E ratio for Celldex stock?
The price to earnings (P/E) ratio for Celldex (CLDX) stock is 0 as of February 18, 2025.
Does Celldex stock pay dividends?
No, Celldex (CLDX) stock does not pay dividends to its shareholders as of February 18, 2025.
When is the next Celldex dividend payment date?
Celldex (CLDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Celldex?
Celldex (CLDX) has a beta rating of 1.59. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.